Kancera reports convincing preclinical results and decision to initiate clinical development of KAND567 in ovarian cancer
Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
Kancera provides operational update in connection with the interim report for the first quarter of 2022
Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), org.nr. 556806-8851
Kancera’s drug candidate KAND145 effectively reduces tumor size in a preclinical model of ovarian cancer
